Saol boards FDA’s resubmission boat, armed with new survival data
Saol boards FDA’s resubmission boat, armed with new survival data (BioSpace.)
Saol Therapeutics
Private
Roswell, GA-based rare disease biotech developing therapies for pain, osteoarthritis, spasticity, and mitochondrial disorders, with a strategic focus on underserved CNS indications.
Company Info
Upcoming Milestones & Key Dates
2026-07-07
regulatory
SL1009 NDA resubmission acknowledged by FDA
2027-H1
regulatory
Expected FDA action on SL1009 NDA
Clinical Development Pipeline
SL1009 (dichloroacetate)
Target: Pyruvate dehydrogenase kinase inhibitorUndisclosed
Target: CNS pathwayUndisclosed
Target: Mitochondrial functionRecent News
Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease
Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease (reported by PR Newswire)
Leadership Team
David R. McClung
Chief Executive Officer
Careers & Job Openings